267 related articles for article (PubMed ID: 10602537)
1. Blood Pressure Monitoring. Task force V: White-coat hypertension.
Pickering TG; Coats A; Mallion JM; Mancia G; Verdecchia P
Blood Press Monit; 1999 Dec; 4(6):333-41. PubMed ID: 10602537
[TBL] [Abstract][Full Text] [Related]
2. Blood Pressure Monitoring. Task force III: Target-organ damage, morbidity and mortality.
Verdecchia P; Clement D; Fagard R; Palatini P; Parati G
Blood Press Monit; 1999 Dec; 4(6):303-17. PubMed ID: 10602535
[TBL] [Abstract][Full Text] [Related]
3. Clinic and ambulatory heart rate in sustained and white-coat hypertension.
Pierdomenico SD; Bucci A; Lapenna D; Cuccurullo F; Mezzetti A
Blood Press Monit; 2001 Oct; 6(5):239-44. PubMed ID: 12055418
[TBL] [Abstract][Full Text] [Related]
4. White-coat resistant hypertension.
Mezzetti A; Pierdomenico SD; Costantini F; Romano F; Bucci A; Di Gioacchino M; Cuccurullo F
Am J Hypertens; 1997 Nov; 10(11):1302-7. PubMed ID: 9397251
[TBL] [Abstract][Full Text] [Related]
5. Task Force II: blood pressure measurement and cardiovascular outcome.
Staessen JA; Asmar R; De Buyzere M; Imai Y; Parati G; Shimada K; Stergiou G; Redón J; Verdecchia P;
Blood Press Monit; 2001 Dec; 6(6):355-70. PubMed ID: 12055415
[TBL] [Abstract][Full Text] [Related]
6. No impact of blood pressure variability on microalbuminuria and left ventricular geometry: analysis of daytime variation, diurnal variation and 'white coat' effect.
Kristensen KS; Høegholm A; Bang LE; Gustavsen PH; Poulsen CB
Blood Press Monit; 2001 Jun; 6(3):125-31. PubMed ID: 11518834
[TBL] [Abstract][Full Text] [Related]
7. Cardiac and arterial target organ damage in adults with elevated ambulatory and normal office blood pressure.
Liu JE; Roman MJ; Pini R; Schwartz JE; Pickering TG; Devereux RB
Ann Intern Med; 1999 Oct; 131(8):564-72. PubMed ID: 10523216
[TBL] [Abstract][Full Text] [Related]
8. Masked, white coat and sustained hypertension: comparison of target organ damage and psychometric parameters.
Konstantopoulou AS; Konstantopoulou PS; Papargyriou IK; Liatis ST; Stergiou GS; Papadogiannis DE
J Hum Hypertens; 2010 Mar; 24(3):151-7. PubMed ID: 19571827
[TBL] [Abstract][Full Text] [Related]
9. Ambulatory blood pressure monitoring and clinical characteristics of the true and white-coat resistant hypertension.
Veglio F; Rabbia F; Riva P; Martini G; Genova GC; Milan A; Paglieri C; Carra R; Chiandussi L
Clin Exp Hypertens; 2001 Apr; 23(3):203-11. PubMed ID: 11339687
[TBL] [Abstract][Full Text] [Related]
10. 'White-coat' hypertension in patients with newly diagnosed hypertension: evaluation of prevalence by ambulatory monitoring and impact on cost of health care.
Pierdomenico SD; Mezzetti A; Lapenna D; Guglielmi MD; Mancini M; Salvatore L; Antidormi T; Costantini F; Cuccurullo F
Eur Heart J; 1995 May; 16(5):692-7. PubMed ID: 7588903
[TBL] [Abstract][Full Text] [Related]
11. Relationship between aortic stiffness and cardiovascular risk factors in a population of normotensives, white-coat normotensives, white-coat hypertensives, sustained hypertensives and diabetic patients.
Silva JA; Barbosa L; Bertoquini S; Maldonado J; Polónia J
Rev Port Cardiol; 2004 Dec; 23(12):1533-47. PubMed ID: 15732656
[TBL] [Abstract][Full Text] [Related]
12. White-coat and masked hypertension in children: association with target-organ damage.
Stabouli S; Kotsis V; Toumanidis S; Papamichael C; Constantopoulos A; Zakopoulos N
Pediatr Nephrol; 2005 Aug; 20(8):1151-5. PubMed ID: 15947982
[TBL] [Abstract][Full Text] [Related]
13. Determinants of the white-coat effect in normotensives and never-treated mild hypertensives.
Tsai PS
Clin Exp Hypertens; 2003 Oct; 25(7):443-54. PubMed ID: 14596368
[TBL] [Abstract][Full Text] [Related]
14. Task force IV: Clinical use of ambulatory blood pressure monitoring. Participants of the 1999 Consensus Conference on Ambulatory Blood Pressure Monitoring.
Staessen JA; Beilin L; Parati G; Waeber B; White W
Blood Press Monit; 1999 Dec; 4(6):319-31. PubMed ID: 10602536
[TBL] [Abstract][Full Text] [Related]
15. [Arterial hypertension difficult to control in the elderly patient. The significance of the "white coat effect"].
Amado P; Vasconcelos N; Santos I; Almeida L; Nazaré J; Carmona J
Rev Port Cardiol; 1999 Oct; 18(10):897-906. PubMed ID: 10590654
[TBL] [Abstract][Full Text] [Related]
16. Target organ status and serum lipids in patients with white coat hypertension.
Pierdomenico SD; Lapenna D; Guglielmi MD; Antidormi T; Schiavone C; Cuccurullo F; Mezzetti A
Hypertension; 1995 Nov; 26(5):801-7. PubMed ID: 7591021
[TBL] [Abstract][Full Text] [Related]
17. White coat hypertension is not a benign entity: a cross-sectional study at a tertiary care hospital in Pakistan.
Godil SS; Tabani H; Khan AH; Almas A
J Pak Med Assoc; 2011 Sep; 61(9):938-43. PubMed ID: 22360048
[TBL] [Abstract][Full Text] [Related]
18. White coat hypertension and target organ involvement: the impact of different cut-off levels on albuminuria and left ventricular mass and geometry.
Høegholm A; Kristensen KS; Bang LE; Nielsen JW
J Hum Hypertens; 1998 Jul; 12(7):433-9. PubMed ID: 9702928
[TBL] [Abstract][Full Text] [Related]
19. Treatment of white coat hypertension.
Chrysant SG
Curr Hypertens Rep; 2000 Aug; 2(4):412-7. PubMed ID: 10981177
[TBL] [Abstract][Full Text] [Related]
20. Cardiac and carotid structure in patients with established hypertension and white-coat hypertension.
Cuspidi C; Marabini M; Lonati L; Sampieri L; Comerio G; Pelizzoli S; Leonetti G; Zanchetti A
J Hypertens; 1995 Dec; 13(12 Pt 2):1707-11. PubMed ID: 8903637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
